Logo image of RCEL

AVITA MEDICAL INC (RCEL) Stock Fundamental Analysis

NASDAQ:RCEL - Nasdaq - US05380C1027 - Common Stock - Currency: USD

5.54  -0.26 (-4.48%)

After market: 5.49 -0.05 (-0.9%)

Fundamental Rating

3

Taking everything into account, RCEL scores 3 out of 10 in our fundamental rating. RCEL was compared to 557 industry peers in the Biotechnology industry. RCEL has a bad profitability rating. Also its financial health evaluation is rather negative. RCEL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCEL had negative earnings in the past year.
In the past year RCEL has reported a negative cash flow from operations.
RCEL had negative earnings in each of the past 5 years.
In the past 5 years RCEL always reported negative operating cash flow.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RCEL's Return On Assets of -82.01% is on the low side compared to the rest of the industry. RCEL is outperformed by 71.02% of its industry peers.
Industry RankSector Rank
ROA -82.01%
ROE N/A
ROIC N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 86.47%, RCEL belongs to the top of the industry, outperforming 89.62% of the companies in the same industry.
In the last couple of years the Gross Margin of RCEL has grown nicely.
RCEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCEL remains at a similar level compared to 1 year ago.
The debt/assets ratio for RCEL is higher compared to a year ago.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.27, we must say that RCEL is in the distress zone and has some risk of bankruptcy.
RCEL has a worse Altman-Z score (-7.27) than 68.34% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.27
ROIC/WACCN/A
WACC9.33%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RCEL has a Current Ratio of 2.09. This indicates that RCEL is financially healthy and has no problem in meeting its short term obligations.
RCEL's Current ratio of 2.09 is on the low side compared to the rest of the industry. RCEL is outperformed by 74.42% of its industry peers.
RCEL has a Quick Ratio of 1.72. This is a normal value and indicates that RCEL is financially healthy and should not expect problems in meeting its short term obligations.
RCEL has a Quick ratio of 1.72. This is in the lower half of the industry: RCEL underperforms 78.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 1.72
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

RCEL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.43%.
RCEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.35%.
The Revenue has been growing by 30.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-24.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.4%
Revenue 1Y (TTM)41.35%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%66.73%

3.2 Future

Based on estimates for the next years, RCEL will show a very strong growth in Earnings Per Share. The EPS will grow by 35.57% on average per year.
Based on estimates for the next years, RCEL will show a very strong growth in Revenue. The Revenue will grow by 38.90% on average per year.
EPS Next Y71.54%
EPS Next 2Y38.75%
EPS Next 3Y39.44%
EPS Next 5Y35.57%
Revenue Next Year48.94%
Revenue Next 2Y38.11%
Revenue Next 3Y39.39%
Revenue Next 5Y38.9%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCEL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as RCEL's earnings are expected to grow with 39.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.75%
EPS Next 3Y39.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVITA MEDICAL INC

NASDAQ:RCEL (6/13/2025, 8:00:02 PM)

After market: 5.49 -0.05 (-0.9%)

5.54

-0.26 (-4.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners26.92%
Inst Owner Change10.35%
Ins Owners0.76%
Ins Owner Change3.22%
Market Cap146.42M
Analysts76.92
Price Target17.21 (210.65%)
Short Float %14.02%
Short Ratio14.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.28%
Min EPS beat(2)-34.96%
Max EPS beat(2)0.41%
EPS beat(4)1
Avg EPS beat(4)-21.86%
Min EPS beat(4)-39.31%
Max EPS beat(4)0.41%
EPS beat(8)3
Avg EPS beat(8)-13.87%
EPS beat(12)6
Avg EPS beat(12)-4.64%
EPS beat(16)10
Avg EPS beat(16)3.01%
Revenue beat(2)0
Avg Revenue beat(2)-14.2%
Min Revenue beat(2)-14.25%
Max Revenue beat(2)-14.15%
Revenue beat(4)1
Avg Revenue beat(4)-7.16%
Min Revenue beat(4)-14.25%
Max Revenue beat(4)1.11%
Revenue beat(8)3
Avg Revenue beat(8)-4.03%
Revenue beat(12)7
Avg Revenue beat(12)1.32%
Revenue beat(16)10
Avg Revenue beat(16)3.26%
PT rev (1m)-3.57%
PT rev (3m)4.17%
EPS NQ rev (1m)15.21%
EPS NQ rev (3m)15.65%
EPS NY rev (1m)0%
EPS NY rev (3m)1.13%
Revenue NQ rev (1m)-0.73%
Revenue NQ rev (3m)-3.18%
Revenue NY rev (1m)-1.39%
Revenue NY rev (3m)-2.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.04
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS2.71
BVpS-0.17
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.47%
FCFM N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
F-Score3
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 570.98%
Cap/Sales 11.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 1.72
Altman-Z -7.27
F-Score3
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)370.65%
Cap/Depr(5y)291.06%
Cap/Sales(3y)6.11%
Cap/Sales(5y)5.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.4%
EPS Next Y71.54%
EPS Next 2Y38.75%
EPS Next 3Y39.44%
EPS Next 5Y35.57%
Revenue 1Y (TTM)41.35%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%66.73%
Revenue Next Year48.94%
Revenue Next 2Y38.11%
Revenue Next 3Y39.39%
Revenue Next 5Y38.9%
EBIT growth 1Y-1.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.45%
EBIT Next 3Y27.19%
EBIT Next 5Y22.17%
FCF growth 1Y-139.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.28%
OCF growth 3YN/A
OCF growth 5YN/A